Journal
SCIENCE
Volume 314, Issue 5796, Pages 126-129Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1129003
Keywords
-
Categories
Funding
- Intramural NIH HHS [Z99 CA999999, Z01 SC003811-32, Z01 BC010763-01] Funding Source: Medline
Ask authors/readers for more resources
Through the adoptive transfer of lymphocytes after host immunodepletion, it is possible to mediate objective cancer regression in human patients with metastatic melanoma. However, the generation of tumor-specific T cells in this mode of immunotherapy is often limiting. Here we report the ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a retrovirus that encodes a T cell receptor. Adoptive transfer of these transduced cells in 15 patients resulted in durable engraftment at levels exceeding 10% of peripheral blood lymphocytes for at least 2 months after the infusion. We observed high sustained levels of circulating, engineered cells at 1 year after infusion in two patients who both demonstrated objective regression of metastatic melanoma lesions. This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available